L-Alanyl/L-Glutamine
Phase 3Small molecule
L-Alanyl/L-Glutamine is one of 42 small molecule programs targeting Acute Kidney Injury. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
178 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Epoetin Beta
RochePhase 3
NORADRENALIN
UUniversity of Aarhus
Phase 3
Nicotinamide Treatment
AAssistance Publique - Hôpitaux de Paris
Phase 3
Crestor
AstraZenecaPreclinical
L-Alanyl/L-Glutamine
TTemple Therapeutics BV
Phase 3
Pentoxyphylline
NNational Taiwan University Hospital
Phase 3
Proamatine
TakedaPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Celexa
AbbViePreclinical
Lexapro
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for L-Alanyl/L-Glutamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTemple Therapeutics BV